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OBJECTIVES: Re-hospitalization andmortality rates are increasingly being used as
quality of care measures that have significant reimbursement implications. We
examine the rates of re-hospitalization and mortality of acute coronary syndrome
(ACS) patients in real-world clinical practice. METHODS: Commercially-insured
patients (age18 years) with an inpatient hospitalization for ACS [ICD-9-CM codes
for acute myocardial infarction or unstable angina (UA)] between 1/1/2007-5/31/
2010 were identified from medical claims in the HealthCore Integrated Research
Database (HIRD). Patients with ACS events within one year prior to index hospital-
izationwere excluded. All-cause andACS-related re-hospitalizations andmortality
rates within 30 days and 12months after index event were evaluated. RESULTS:Of
66,772 ACS patients (60%male; mean age 66.6 years), 21% had diagnostic coding for
ST elevation myocardial infarction (STEMI), 31% had coding for non-ST elevation
myocardial infarction (NSTEMI), 37% had UA, and 11% had not otherwise specified
(NOS) ACS. Approximately, 90% and 52%of patients had30-days and 12months
of continuous eligibility respectively. The 30-day all-cause re-hospitalization rate
was 16.3 % (STEMI: 16.4%, NSTEMI: 19.0%, UA: 13.3%, NOS: 20.6%;) and 6.3 % (STEMI:
8.8%, NSTEMI: 6.6%, UA: 5.2%, NOS: 4.5%) for anACS-related re-hospitalization. The
12-month all cause re-hospitalization rate was 41.3% (STEMI: 39.0%, NSTEMI:
46.4%, UA: 38.2%NOS: 46.6%, )and 16.6% for an ACS-related re-hospitalization. The
30-day post-index mortality rate was 2.4 % (STEMI:1 .8%, NSTEMI:4.3%, UA:0.5%,
NOS:5.2%;) and the 12-month rate was 7.0%. For patients with ages  65 years, the
30-day all-cause and ACS-related re-hospitalization rates were 21.2% and 7.0%,
respectively. CONCLUSIONS: The re-hospitalization and mortality rate for ACS
patients within 30 days and 12-months post-index hospitalization discharge as
observed in real-world clinical practice remain high. Use of more effective thera-
pies may provide an opportunity to improve important clinical and economic out-
comes in ACS patients.
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OBJECTIVES: Cost-effectiveness analysis is now well established in relation to the
evaluation of health technologies, but not in relation to broader institutional level
variations in clinical pathways. Linked, routinely collected data provides an oppor-
tunity to evaluate real world activity. A novel approach to analysing the risk-ad-
justed cost-effectiveness (RAC-E) of acute services for patients presenting with
chest pain at the four main public hospitals in South Australia is presented.
METHODS: Routinely collected data on hospital separations (including costs) and
mortality records were linked deterministically. Relevant intermediate endpoints
over a two year follow-up period in a cohort of patients presenting with chest pain
in the year to July 2006 were identified. Lifetime costs and survival were extrapo-
lated from these endpoints using data fromchest pain patients presenting between
July 2002 and June 2008. The resulting estimates of costs and survival were stan-
dardized using separate regression models that estimated expected cost and sur-
vival values for each patient. RESULTS: In the base case, two of the four hospitals
were dominated by hospital 1. Hospital 2 had lower standardized lifetime costs
than hospital 1, and the incremental cost per life year gained between these two
hospitals was Aus$2,909. A bootstrapped probabilistic sensitivity analysis showed
hospital 1 to have very high probabilities of cost-effectiveness at relevant dollar
values for a life year gained. Analysis of differences in cost components between
the hospitals showed that hospital 1 spent relatively less on pathology and imag-
ing, whilst spending more on nursing time and pharmaceuticals. CONCLUSIONS:
RAC-E provides a useful framework for identifying important differences in the
costs and benefits associated with variations in clinical practice. Potential deter-
minants can be partially investigatedwith the data, but further primary analysis of
clinical pathways at key hospitals is required to fully inform the dissemination of
best practice.
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OBJECTIVES: We examine current treatment patterns associated with the use of
antiarrhythmics for pharmacologic cardioversion and evaluate time to conversion
among patients with acute atrial fibrillation (AF) in France, Italy, Germany, Spain,
and UK.METHODS: Data were collected cross-sectionally as observed by 303 phy-
sicians from April to June 2010. RESULTS: Among 2,997 patients, 1,352 (45%) re-
ceived pharmacologic cardioversion only, with 1,082 (80%) successfully cardiovert-
ing. Of these, 931 (69% of those treated pharmacologically, 86% of those
successfully) had complete information on time to achieve sinus rhythm andwere
further assessed here. Amiodarone was administered to most (49%), with similar
proportions receiving intravenous (IV) (53%) and oral (46%) formulations. Amioda-
rone IV was associated with a significantly shorter median conversion time (8
hours) compared to oral (36 hours). Patients treated with flecainide (26%) had the
shortest median time to cardioversion (4 hours), while patients on propafenone
(15%) were next (6 hours). Median cardioversion time varied by country. Specifi-
cally, patients in France took longer to convert on amiodarone IV and oral at a
median time of 12 and 48 hours compared to an average of 7 and 24 hours, respec-
tively, in other countries. In Germany, little difference was observed with median
conversion times of 9 and 10 hours for amiodarone IV and oral, respectively. Me-
dian conversion times were also similar between amiodarone IV and flecainide in
Spain and Italy (a difference of 1 and 2 hours, respectively) compared to an average
difference inmedian conversion time of 4 hours between these treatments overall.
CONCLUSIONS: While amiodarone had a longer median time to cardioversion,
faster acting agents, such as flecainide and propafenone, had conversion times
substantially longer than their known time of action, reflecting other influences on
treatment administration. Differences in conversion time suggest country- and
physician-specific practices in the use of pharmacologic cardioversion therapies.
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OBJECTIVES: Epidemiological models have been widely used to estimate how in-
creased uptakes of medical and surgical treatments affect mortality and related
outcomes. Standard methods rely on the estimate of the case fatality, defined as
the risk of death in the absence of the treatment. Because most patients receive
some treatment, mortality rates where some treatment is present are often used
instead of case fatality rates, leading to biased results. A method that does not rely
on case fatality estimates is needed. METHODS: We borrow the mechanism used
for the calculation of the Potent Impact Fraction (PIF), an epidemiological measure
that is equal to the proportional reduction in the incidence of a disease ormortality,
resulting froma specific change in the distribution of a risk factor in the population,
and apply it to the estimation of the relative reduction of mortality caused by the
increase of treatment uptake in the population at risk. We apply this method to
estimate the reduction of cardiovascular disease deaths in Ontario, if treatment
rates for CHD interventions were to be increased from 2005 levels to the recom-
mended benchmark utilization of 90%. TheMant-Hicksmodel for polypharmacy is
adopted, while the uptakes of multiple treatments are assumed to be independent
from each other. RESULTS: Using the proposed PIF-based method, we estimated
that increasing treatment to benchmark levels uptake results in a reduction of
cardiovascular mortality of 22.5%. The standard method gives a reduction of 17%,
probably due to underestimation of the case fatality.CONCLUSIONS:Herewe pres-
ent an alternative method for the estimation of the effect of treatment uptake
increase to the reduction ofmortality. Our example suggests that themagnitude of
bias associated with the standard method may be substantial. This approach may
be a useful tool for epidemiological and health care research.
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OBJECTIVES: To develop and validate a disease-specific health status measure for
individuals with myocardial infarction (MI). METHODS: The development of the
Myocardial Infarction Dimensional Assessment Scale (MIDAS) followed threemain
stages. Stage 1 consisted of in-depth, semi-structured, exploratory interviews con-
ducted on a sample of 31 patients to identify areas of salience and concern to
patientswithMI. These interviews generated 48 candidate questions. In stage 2 the
48-item questionnaire was used in a postal survey to identify appropriate rephras-
ing/shortening, to determine acceptability and to help identify sub-scales of the
instrument addressing different dimensions of MI. Finally, in stage 3 the construct
validity of MIDAS subscales was examined in relation to clinical and other health
outcomes. Setting - A single centre (district general hospital) in England was used
for stages 1 and 3 and a national postal surveywas conducted for stage 2. Patients - A
total of 410 patients were recruited for the national survey (stage 2). Full data was
available on 348 (85%) patients. 155 patients were recruited to test construct valid-
ity (stage 3). RESULTS: The MIDAS contains 35 questions measuring seven areas of
health status: physical activity, insecurity, emotional reaction, dependency, diet,
concerns overmedication and side effects. Themeasure has high face, internal and
construct validity and is likely to prove useful in the evaluation of treatment re-
gimes for MI. CONCLUSIONS: The MIDAS has acceptable validity and reliability. It
is suitable for use in a variety of settings for patients with myocardial infarction.
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